Auris Medical Holding AG(NASDAQ:EARS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 18, 2016. Earnings per share were $-0.26. Analysts had estimated an EPS of $-0.25.
Auris Medical Holding AG (EARS) shares turned negative on Mondays trading session with the shares closing down -0.04 points or -1.93% at a volume of 2,49,649. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $2.06. The peak price level was also seen at $2.06 while the days lowest was $2.01. Finally the shares closed at $2.03. The 52-week high of the shares is $7.96 while the 52-week low is $1.95. According to the latest information available, the market cap of the company is $70 M.
Auris Medical Holding AG is a holding company. The Company is a development-stage biopharmaceutical company. The Company’s advanced product candidate is AM-101 for acute inner ear tinnitus. It is also developing AM-111 for acute inner ear hearing loss. Its product candidates are injected under local anesthesia into the middle ear by a technique called intratympanic or i.t. injection. The Company is also engaged in preclinical studies of AM-102 and AM-123. AM-101 is formulated in a biocompatible gel. AM-111 contains a synthetic D-form peptide (D-JNKI-1) that protects sensorineural structures in the inner ear from stress-induced damage. AM-111 is being developed for the treatment of autoimmune sensorineural hearing loss (ASNHL).